HER2-positive breast cancer therapy. Tucatinib. Trastuzumab deruxtecan. 4

HER2-positive breast cancer therapy. Tucatinib. Trastuzumab deruxtecan. 4

HER2-positive breast cancer therapy. Tucatinib. Trastuzumab deruxtecan. 4

Can we help?

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HER2-positive breast cancer is diagnosed in up to 20% of all breast cancer cases. HER2-positive breast cancer tends to be more aggressive. So it might have a worse prognosis historically. What are the nuances of HER2-positive breast cancer therapy that we can observe today? What are some advanced treatments on the horizon in the near future?

I believe there are two most promising medications for HER2-positive breast cancer. One is already in current use. It is Tucatinib, a small-molecule tyrosine kinase inhibitor. It demonstrated in the third-line setting an overall survival and progression-free survival benefit. Also, in patients with metastatic brain lesions from breast cancer, that is an unmet medical need. And the other drug is for sure trastuzumab deruxtecan. This is an antibody-drug conjugate with very high potency for HER2-positive disease. In my opinion, trastuzumab deruxtecan can potentially be a new standard of care in the first-line setting of HER2-positive breast cancer. Let me also tell you this. I am quite sure that if we treat all oligometastatic breast cancer diseases, some of these patients can be potentially cured with this new type of approach. In my opinion, antibody-drug conjugates will be new smart chemotherapies that will substitute completely standard chemotherapy in the future.

So this mostly applies to metastatic advanced HER2-positive breast cancer. Is there anything on the horizon for the early primary diagnosis the HER2-positive breast cancer?

Yes, we will start with a new clinical trial using antibody drug-conjugate in the neoadjuvant setting for HER2-positive breast cancer. So the idea is to compare trastuzumab deruxtecan to standard chemotherapy, which is Trastuzumab and Pertuzumab in early HER2-positive breast cancer patients.

More from Breast Cancer
Seek second opinion from a clinical physician or surgeon. Not from a radiologist. 15
$0.00
Breast cancer, obesity, and insulin. How metformin helps to delay cancer. 3
$0.00
Hormone-resistant breast cancer. New endocrine therapy of cancer. 2
$0.00
How to prevent breast cancer? Chemoprevention with aromatase inhibitors. 10
$0.00
Early breast cancer, DCIS. How to decide on best therapy? 3
$0.00
Tumor markers in DCIS breast cancer. Prediction of endocrine treatment and radiotherapy. 2
$0.00
Recently viewed Expert Conversations

Refine your treatment plan to perfection by a panel of 3 to 10+ top doctors that are perfect for you.

Refine your treatment plan to perfection by a panel of 3 to 10+ top doctors that are perfect for you.

Refine your treatment plan to perfection by a panel of 3 to 10+ top doctors that are perfect for you.


Can we help?

Find perfect surgeons or medical specialists to perform your treatment.

Find perfect surgeons or medical specialists to perform your treatment.


How it works
Find perfect surgeons or medical specialists to perform your treatment.